The following was posted on the MSRC website:
Sales of the multiple-scelrosis drug totaled $1.18 billion in 2005, 26% more than in 2004.
Teva Pharmaceutical Industries Ltd. has announced, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of its multiple-sclerosis drug Copaxone reached $323 million in the fourth quarter of 2005, representing an increase of 24% over the comparable quarter of 2004.
For the full year 2005, global in-market sales of Copaxone reached an all-time high of $1,176 million, representing an increase of 26% over 2004.
US sales in the fourth quarter 2005 rose 26% over the fourth quarter 2004 to $220 million. For the full year 2005, US sales rose 25% compared with 2004, to $782 million
Teva says that, according to IMS data in the US, Copaxone continued to strengthen its position as market leader, reaching an all time record market share of 34.3% in December 2005.
For the fourth quarter 2005, sales outside the US, mainly in Europe, increased by 19% over the comparable quarter of 2004, to $103 million. For the entire year, sales outside the US increased by 27% to $394 million.
Source: by Globes, Israel business news
The CRAB manufacturers are all posting big increases in revenue. Does this mean MS is on the rise or have prices gone up?
For other drugs the patents run out and other manufacturers can make them and sell them cheaper. Why does this not happen with MS drugs some of which have been around for 15 years?
My Rebif box arrived on Friday. I called the nurse today who is coming round to teach me how to inject. She said that she has been inundated with calls from new-starters this morning!